ANAPTYSBIO, INC. Form DEFA14A: Additional definitive proxy soliciting materials
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2026-06-29: Form DEFA14A; Description DEFA14A; Document anab_2025_proxy_addl_mat.htm.
- 2025-04-29: Form DEFA14A; Description DEFA14A; Document proxystatementadditionalma.htm.
- 2024-04-24: Form DEFA14A; Description DEFA14A; Document proxystatementadditionalma.htm.
- 2023-04-27: Form DEFA14A; Description DEFA14A; Document proxystatementadditionalma.htm.
| Filed | Form | Period of report | Description | Document |
|---|---|---|---|---|
| 2026-06-29 | DEFA14A | DEFA14A | anab_2025_proxy_addl_mat.htm | |
| 2025-04-29 | DEFA14A | DEFA14A | proxystatementadditionalma.htm | |
| 2024-04-24 | DEFA14A | DEFA14A | proxystatementadditionalma.htm | |
| 2023-04-27 | DEFA14A | DEFA14A | proxystatementadditionalma.htm | |
| 2022-04-29 | DEFA14A | DEFA14A | proxystatementadditionalma.htm | |
| 2021-04-26 | DEFA14A | DEFA14A | proxystatementadditionalma.htm | |
| 2020-04-27 | DEFA14A | DEFA14A | proxystatementadditionalma.htm | |
| 2019-04-26 | DEFA14A | DEFA14A | proxystatementadditionalma.htm | |
| 2018-04-26 | DEFA14A | DEFA14A | proxystatementadditionalma.htm |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |